COLUMBIA, Md., May 1, 2013 /PRNewswire/ -- ACell, Inc., a leading developer of next-generation regenerative medicine products, announced today that it has received the Space Medicine and Related Technologies Commercialization Assistance Program (SMARTCAP) award, given by National Space Biomedical Research Institute's (NSBRI) Industry forum. The award will support ACell in the development of innovative new medical devices that address unmet health needs in space and on Earth, specifically in the area of wound care.
(Logo: http://photos.prnewswire.com/prnh/20130424/PH00029LOGO )
"By developing new unique solutions for medical care in space, we are also making an impact on health care on Earth. Because the bar is set high for medical care in space, technologies developed for space generally possess unique features that translate to a competitive commercial advantage in Earth markets," said Dr. Dorit Donoviel, NSBRI deputy chief scientist and Industry Forum lead.
"ACell appreciates the opportunity provided by SMARTCAP, which will enable us to advance our tissue regeneration platform technology and develop the next-generation wound care medical device used to aid humans in space as well as patients here on Earth," said Rodney Bosley, ACell President & COO.
The SMARTCAP award also aims to position selected companies for follow-up support from investors, potential industry partners, or other funding entities to further accelerate product innovation. NSBRI is funded by NASA and includes twelve academic institutions studying the health risks related to long-duration spaceflight and developing the medical technologies needed for long missions. Their primary objective is to ensure safe and productive human spaceflight. To learn more about NSBRI, visit www.nsbri.org.
For more information on ACell and its leading MatriStem tissue regeneration platform, please visit www.acell.com.
ACell, Inc. is a leading developer, manufacturer and marketer of next-generation regenerative medicine products. Its products are cleared for a variety of indications and are marketed under the brand name "MatriStem." A privately held Company, Acell produces MatriStem in its manufacturing facilities and markets its products to physicians in the U.S. through a national direct sales force. For more information, call (800) 826-2926 or visit www.acell.com.
MatriStem Products consist of porcine-derived extracellular matrix (ECM) that maintain and support a healing environment through constructive remodeling, and are available in particle and sheet forms by prescription only. These devices, trademarked as MatriStem, are appropriate for acute wounds, chronic wounds and various surgical procedures. All MatriStem devices are made in the USA. Refer to IFU supplied with each device for indications, contraindications, and precautions.
SOURCE ACell, Inc.